Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.
Saratoga Health & Biotechnology I SBHIX
- NAV / 1-Day Return 25.13 / +1.17 %
- Total Assets 12.4 Mil
-
Adj. Expense Ratio
- Expense Ratio 2.350%
- Distribution Fee Level High
- Share Class Type Institutional
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 250
- Status Open
- TTM Yield —
- Turnover 58%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0
Morningstar’s Analysis SBHIX
Will SBHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.7
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Regeneron Pharmaceuticals Inc | 5.50 | 656,707 | Healthcare |
Amgen Inc | 5.10 | 609,253 | Healthcare |
McKesson Corp | 5.01 | 598,070 | Healthcare |
Tenet Healthcare Corp | 4.90 | 584,556 | Healthcare |
Cencora Inc | 4.87 | 581,152 | Healthcare |
Elevance Health Inc | 4.09 | 488,940 | Healthcare |
The Cigna Group | 3.96 | 472,474 | Healthcare |
United Therapeutics Corp | 3.82 | 455,890 | Healthcare |
Intuitive Surgical Inc | 3.77 | 450,374 | Healthcare |
Thermo Fisher Scientific Inc | 3.65 | 436,209 | Healthcare |